Enveda Biosciences, a clinical-stage biotech company specializing in AI-powered drug discovery from natural compounds, has announced a $150 million Series D funding round, propelling the company to unicorn status. This milestone follows the enrollment of the first patient in a Phase 1b clinical trial for its lead program, ENV-294, targeting atopic dermatitis, and the addition of Dr. Mikael Dolsten, former Pfizer Chief Scientific Officer, to its Board of Directors.
Accelerating Drug Discovery with AI
Enveda’s proprietary platform integrates machine learning and metabolomics to decode complex natural chemistry, enabling the rapid identification of novel small molecules with therapeutic potential. The company has developed one of the world’s largest collections of natural samples, making nature’s chemical diversity searchable and actionable. This approach allows Enveda to advance drug candidates four times faster and at one-tenth the cost of traditional methods.
Also Read: GE HealthCare Launches Vivid Pioneer AI Cardiovascular Ultrasound
Expanding Clinical Pipeline
The Series D funding will support the progression of multiple clinical programs into Phase 1b and Phase 2 trials across various indications, including atopic dermatitis, asthma, inflammatory bowel disease, and obesity. The funds will also facilitate new Investigational New Drug (IND) filings, positioning Enveda to deliver key clinical milestones in the coming months.
Implications for AI and Healthcare Professionals
Enveda’s advancements underscore the growing intersection of artificial intelligence and biotechnology in drug discovery. The company’s ability to harness AI to explore the vast chemical space of natural compounds offers new avenues for developing treatments for complex diseases. For professionals in life sciences, biotech, and healthcare, Enveda’s progress represents a significant step forward in the application of AI to address unmet medical needs.
